Human SNP Links Differential Outcomes in Inflammatory and Infectious Disease to a FOXO3-Regulated Pathway

James C. Lee,1,2 Marion Espéli,1,2 Carl A. Anderson,3 Michelle A. Linterman,1,2 Joanna M. Pocock,1,2 Naomi J. Williams,4 Rebecca Roberts,5 Sebastien Viatte,6 Bo Fu,6,7 Norbert Pesu,2 Tran Tinh Hien,2 Nguyen Hoan Phu,8 Emma Wesley,11 Cathryn Edwards,11 Tariq Ahmad,11 John C. Mansfield,13 Richard Geary,7 Sarah Dunstan,11,14 Thomas N. Williams,8,15 Anne Barton,2 Carola G. Vinuesa,9 UK IBD Genetics Consortium,16 Miles Parkes,2 Paul A. Lyons,1,2 and Kenneth G.C. Smith1,2,*

1Cambridge Institute for Medical Research, University of Cambridge, Cambridge Biomedical Campus, Cambridge CB2 0XY, UK
2Department of Medicine, University of Cambridge School of Clinical Medicine, Addenbrooke’s Hospital, Cambridge CB2 0QQ, UK
3Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SA, UK
4Department of Pathogens and Immunity, John Curtin School of Medical Research, Australian National University, Canberra ACT 2601, Australia
5University of Otago, Department of Medicine, Christchurch 8011, New Zealand
6Arthritis Research UK Epidemiology Unit, Manchester Academic Health Science Center, University of Manchester, Manchester M13 9PT, UK
7Centre for Biostatistics, Institute of Population Health, University of Manchester, Manchester M13 9PL, UK
8Kenya Medical Research Institute/Wellcome Trust Research Program, Centre for Geographic Medicine Research, Kilifi P.O. Box 230-80108, Kenya
9Oxford University Clinical Research Unit, Wellcome Trust Major Overseas Program, Hospital for Tropical Diseases, District 5 Ho Chi Minh City, Vietnam
10The Hospital for Tropical Diseases, District 5 Ho Chi Minh City, Vietnam
11Peninsula College of Medicine and Dentistry, University of Exeter, Exeter EX2 5DW, UK
12Department of Gastroenterology, Torbay Hospital, Torquay TQ2 7AA, UK
13Institute of Genetic Medicine, Newcastle University, Newcastle NE1 3BZ, UK
14Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Oxford OX3 7LJ, UK
15Department of Medicine, Imperial College, London SW7 2AZ, UK
16A full list of The UK IBD Genetics Consortium contributors may be found in the Supplemental Information

*Correspondence: kgcs2@cam.ac.uk

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-No Derivative Works License, which permits non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited.

SUMMARY

The clinical course and eventual outcome, or prognosis, of complex diseases varies enormously between affected individuals. This variability critically determines the impact a disease has on a patient’s life but is very poorly understood. Here, we exploit existing genome-wide association study data to gain insight into the role of genetics in prognosis. We identify a noncoding polymorphism in FOXO3A (rs12212067: T > G) at which the minor (G) allele, despite not being associated with disease susceptibility, is associated with a milder course of Crohn’s disease and rheumatoid arthritis and with increased risk of severe malaria. Minor allele carriage is shown to limit inflammatory responses in monocytes via a FOXO3-driven pathway, which through TGFβ1 reduces production of proinflammatory cytokines, including TNFα, and increases production of anti-inflammatory cytokines, including IL-10. Thus, we uncover a shared genetic contribution to prognosis in distinct diseases that operates via a FOXO3-driven pathway modulating inflammatory responses.

INTRODUCTION

Insights obtained from genetic experiments, including genome-wide association studies (GWASs), have substantially advanced our understanding of complex disease biology, and specifically of the processes that drive disease development (Jostins et al., 2012). It is important to remember, however, that disease development is only one aspect of disease biology. Equally important from a clinical standpoint is the biology that determines the course a disease takes following its development (prognosis). Variability in prognosis is observed in most complex diseases and directly impacts upon patient well-being, often to a greater extent than the diagnosis itself. Despite this, the determinants of prognosis in most diseases remain poorly understood and largely unaddressed by those genetic technologies that have yielded such insights into disease development.
This knowledge imbalance is exemplified in Crohn’s disease (CD), a chronic, relapsing-remitting form of inflammatory bowel disease thought to be driven by aberrant immune responses to intestinal bacteria. CD has been a major beneficiary of GWAS technology, with over 140 risk loci having been identified (Jostins et al., 2012), though only one of these has been shown to correlate with clinical outcome in CD (Hellö et al., 2003). Such observations have led to criticisms of the utility of GWAS results in translational medicine (McClellan and King, 2010) and raise questions as to whether genetics meaningfully contributes to prognosis in complex disease.

We have recently shown that common transcriptional differences involving the IL-2 and IL-7 cytokine-signaling pathways correlate with prognosis in several diseases, including CD (McKinney et al., 2010; Lee et al., 2011). Here, we perform a candidate gene study to address whether genetic variation in these immune pathways, which have not been associated with the development of CD, might associate with disease prognosis and, if so, to understand the biological mechanisms responsible. To answer this question, we determined that a “within-cases” association analysis would be required, in which the genetic profiles of patients with contrasting disease courses could be directly compared. To achieve this, we used a subset of genotypic data relating to the IL-2 and IL-7 pathways from an existing GWAS data set (Wellcome Trust Case Control Consortium, 2007) and exploited allied phenotypic data to identify groups of patients with either particularly aggressive or indolent CD. This led to the identification of a noncoding single-nucleotide polymorphism (SNP) in FOXO3A that associates with prognosis in CD, despite not being a disease- associated variant (Jostins et al., 2012). FOXO3A encodes FOXO3, a member of the forkhead box O family of transcription factors, which also includes FOXO1 and FOXO4 (Accili and Arden, 2004). These proteins are widely expressed and regulate diverse transcriptional programs including cell-cycle control, metabolism, regulatory T cell development, and apoptosis (Burgering and Kops, 2002; Modur et al., 2002; Nakae et al., 2008; Harada et al., 2010; Kerdiles et al., 2010; Ouyang et al., 2010). Although many of these roles are redundant between FOXO family members (Accili and Arden, 2004), FOXO3 has been reported to have nonredundant roles in suppressing inflammatory cytokine production by dendritic cells (Dejean et al., 2009; Watkins et al., 2011) and in limiting the inflammatory sequelae of viral infections (Litvak et al., 2012). Here, we show that during inflammatory responses, in which FOXO3 is exported from the nucleus to the cytoplasm, its reaccumulation in the nucleus is dependent on transcription and de novo protein production, and demonstrate that allelic variation at the prognosis-associated SNP regulates this reaccumulation by controlling FOXO3A transcription. Earlier recovery of nuclear FOXO3, which occurs if the indolent disease-associated allele is present, initiates a TGFB1-dependent pathway in monocytes that reduces production of proinflammatory cytokines, including TNFα, and increases production of the anti-inflammatory cytokine, IL-10—changes consistent with a more indolent disease course. Furthermore, we show that genetic variation at this SNP is also associated with prognosis in rheumatoid arthritis and malaria—other diseases in which these cytokines are implicated. These associations were consistent with the role for these cytokines in each disease, and suggest that this pathway may be generally important in diseases in which these cytokines are involved. Collectively, therefore, these data reveal a pathway by which FOXO3 can abrogate inflammatory responses, and uncover a shared genetic contribution to the prognosis of distinct diseases that impacts upon this pathway and is distinct from the genetic contribution to disease development.

RESULTS

Prognosis-Based Association Study in Crohn’s Disease

Subgroups of patients with either particularly aggressive or indolent CD were identified within an existing GWAS cohort (Wellcome Trust Case Control Consortium, 2007) using phenotypic data. Aggressive CD (n = 668) was defined as that for which two or more immunomodulator therapies and/or intestinal resections had been required (treatments reserved for patients with frequently flaring or complicated CD). Indolent CD (n = 389) was defined as disease of greater than 4 years duration, for which immunomodulators or intestinal resections had never been required. Eighty-one genes involved in IL-2 or IL-7 signaling were identified from published literature and pathway libraries (KEGG, Kanehisa and Goto, 2000; Biocarta, http://www.biocarta.com) (Table S1 available online). These pathways were selected because we have previously shown that differences within them correlate with prognosis in several diseases, including CD, and yet unlike a number of other disease-associated cytokines, they have not been implicated in disease development (McKinney et al., 2010; Lee et al., 2011). The allele frequency at 1,134 SNPs within these genes was then compared between the indolent and aggressive CD subgroups (Figure S1). The effect of population structure on the results was assessed by three separate methods and shown to be minimal (genomic control inflation factor 1.04, see Extended Experimental Procedures). Replication of the three most significant associations was then sought in three independent cohorts, each similarly divided into indolent and aggressive cases (Table S2). The prognostic association of rs12212067, an intronic SNP within FOXO3A, was replicated in all three cohorts, with the minor (G) allele being consistently more common in patients with indolent CD (combined p value = 2.1 × 10⁻⁸, Tables 1 and S3). Notably, this SNP was not associated with risk for CD either in the GWAS used for this study (p = 0.88)—a sample of 1,748 cases and 2,938 controls (Wellcome Trust Case Control Consortium, 2007)—or in a larger meta-analysis (p = 0.99) of 6,333 cases and 15,056 controls (Franke et al., 2010), which suggests that if it does influence disease risk, its effect size is negligible.

rs12212067 Regulates Transcription of FOXO3A during Inflammation

To investigate how genetic variation at this locus might influence prognosis in CD, we first examined whether rs12212067 was in linkage disequilibrium (LD) with a coding variant that could affect protein structure or function. Using sequence data from the 1000 Genomes Project Consortium et al. (2010) we identified all of the SNPs in LD (r² > 0.5) with rs12212067, but none of these were exonic (Table S4 and Figure S2). Indeed, of the 45 coding variants that have been described within FOXO3A (dbSNP,
Table 1. Association of rs12212067 with Prognosis in CD

| Cohort                      | n    | MAF (Aggressive) | MAF (Indolent) | Odds Ratio (95% CI) | p Value |
|-----------------------------|------|------------------|----------------|---------------------|---------|
| Primary cohort (WTCCC CD GWAS) | 1,057 (668, 389) | 0.084 | 0.131 | 0.61 (0.46–0.83) | 6.16 × 10⁻⁴ |
| Replication cohort 1 (UK - TaqMan) | 701 (344, 357) | 0.094 | 0.129 | 0.71 (0.49–1.00) | 0.025 |
| Replication cohort 2 (NZ - TaqMan) | 226 (136, 90) | 0.070 | 0.128 | 0.51 (0.26–1.02) | 0.029 |
| Replication cohort 3 (UK - Immunochip) | 1,001 (670, 331) | 0.083 | 0.133 | 0.59 (0.44–0.81) | 6.50 × 10⁻⁴ |
| Combined analysis           | 2,985 (1,818, 1,167) | 0.084 | 0.131 | 0.62 (0.52–0.73) | 2.09 × 10⁻⁸ |

Aggressive CD, patients requiring ≥ two immunomodulators and/or intestinal resections; Indolent CD, patients with > 4 years follow-up, no immunomodulators or intestinal resections. p values calculated with Cochran-Armitage test (primary cohort) and Fisher’s exact test (replication cohorts and combined analysis). Odds ratios refer to the minor (G) allele and aggressive Crohn’s disease (CD). WTCCC, Wellcome Trust Case Control Consortium; UK, United Kingdom; NZ, New Zealand; MAF, minor allele frequency; CI, confidence interval. See also Figure S1 and Tables S1, S2, S3, S4.

*Total sample size (Aggressive, Indolent).

http://www.ncbi.nlm.nih.gov/projects/SNP) none were in any demonstrable LD with rs12212067: T > G (r² < 0.001, data not shown). This implies that noncoding variation is likely to drive the association. The majority of complex disease-associated SNPs are also noncoding and are assumed to affect gene expression, though in most cases this has not been confirmed (McClellan and King, 2010). To ascertain whether rs12212067: T > G, or a variant in strong LD with it, might influence gene expression, we used a cloned based allele-specific expression assay to analyze FOXO3A transcription in monocytes from heterozygous individuals (obtained from a genotype-selectable bioresource: http://www.cambridgebioresource.org.uk). This facilitates a direct comparison between the amount of FOXO3A pre-mRNA that is transcribed from each allele or haplotype and ensures that external factors affect both alleles equally. Under basal (unstimulated) conditions, the ratio of major (T) to minor (G) alleles in FOXO3A pre-mRNA was different to that observed in genomic DNA (in which it is inherently 1:1), indicating that allele-specific expression did not occur. However, following stimulation with lipopolysaccharide (LPS), a Toll-like receptor 4 (TLR4) ligand, we observed consistent allele-specific differences in transcription, with over twice as much FOXO3A being transcribed from the DNA strand containing the minor G allele (associated with indolent CD) than from the strand containing the major T allele (Figure 1A).

**Genetic Variation at rs12212067 Modulates Inflammatory Cytokine Production by Monocytes**

To determine whether this difference in FOXO3A transcription had functional consequences, we stimulated peripheral blood mononuclear cells (PBMC) from healthy individuals, who were homozygous for either the minor or major allele at rs12212067, and measured cytokine production. We initially focused upon TNF-α, the archetypal proinflammatory cytokine in CD (Khor et al., 2011) and target of the most effective medical therapy (Krygier et al., 2009); and IL-10, an anti-inflammatory cytokine, which when deleted produces one of the best mouse models of IBD (Rennick et al., 1997); and genetic variants of which are associated with CD (Jostins et al., 2012). Following LPS stimulation, we observed striking genotype-specific differences in the production of these cytokines, with PBMC from minor (G) allele homozygotes secreting less TNF-α than those from major (T) allele homozygotes. PBMC from minor allele homozygotes also secreted relatively more IL-10 in response to higher concentrations of LPS (Figure 1B). This pattern of cytokine production implies that, under these conditions, minor allele homozygotes generate lesser inflammatory responses. There were no genotype-specific differences in the proportion, activation status or immunophenotype of leukocyte subsets within PBMC that could explain this result (Table S3). These included regulatory T cells and dendritic cells, in which FOXO3 has specific roles (Dejean et al., 2009; Kerdiles et al., 2010).

To ascertain which cell population was responsible for the differences in cytokine production, we used flow cytometry to identify the TNF-α and IL-10 producing cells. Following stimulation with LPS (100 ng/ml), production of both cytokines could be detected within CD14⁺ monocytes, but not within CD3⁺ T cells or CD19⁺ B cells (Figure 1C). Of note, differences were again observed between the genotypes, with less TNF-α and more IL-10 being produced by monocytes from minor allele homozygotes (Figure S3). To determine whether this phenomenon was cell-intrinsic or due to another cell type influencing monocyte cytokine production, we purified monocytes and stimulated them in isolation. Despite removing the influence of other cell types, we observed the same genotype-specific differences in cytokine production (Figure 1D), implying that the effect was monocyte intrinsic. We then examined whether the differences were specific to stimulation via TLR4 or would also occur with other TLR ligands (Pam3Cys4 [TLR1/2], Poly(I:C) [TLR3], Flagellin [TLR5], and CpG [TLR9]). We observed the same reciprocal differences in TNF-α and IL-10 production in response to all of these ligands except Poly(I:C), which induced little TNF-α and IL-10 production consistent with previous reports (Lundberg et al., 2007) (Figure 1E). Thus, the genotype-specific differences in cytokine production arise from monocytes but can be induced by several pathogen-associated molecular patterns.

We then examined the production of other proinflammatory cytokines to determine whether these also differed by genotype. We quantified GM-CSF, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, and IL-12p40 and observed that, as well as producing less TNF-α, monocytes from minor (G) allele homozygotes also produced less IL-1β, IL-6, and IL-8 compared to those from major (T) allele homozygotes (Figures 1F and S4). Notably, these cytokines constitute a major part of the innate immune response to pathogens (Auffray et al., 2009) and can influence the phenotype of T cells (Dejean et al., 2009).
Figure 1. Genotype at rs12212067 Drives Allele-Specific Expression of FOXO3A and Modulates Inflammatory Cytokine Production in Monocytes

(A) Allele-specific expression assay showing the ratio of rs12212067 alleles in genomic DNA (gDNA) and complementary DNA (cDNA; synthesized from pre-mRNA) from peripheral monocytes of heterozygous individuals. Ninety-six colonies were genotyped per individual per condition (either unstimulated [unstim.] or stimulated with 100 ng/ml LPS [stim.]; n = 6.

(B) TNFα and IL-10 production by PBMC from minor (G) and major (T) allele homozygotes at rs1221267 following 24 hr stimulation with LPS; n = 15 per group, assayed in triplicate.

(C) Intracellular staining of TNFα and IL-10 production in LPS-stimulated (100 ng/ml) CD3⁺ T cells, CD19⁺ B cells and CD14⁺ monocytes. Isotype control shown as shaded histogram. Results representative of 20 experiments.

(D) TNFα and IL-10 production by purified monocytes from minor and major allele homozygotes following 24 hr stimulation with LPS (100 ng/ml); n = 11 per group, assayed in triplicate. 20 of these individuals had provided samples used in B.

(E) TNFα and IL-10 production by PBMC from minor and major allele homozygotes following 24 hr stimulation with other TLR ligands; n = 11 per group (same individuals’ samples as D), assayed in triplicate.

(F) IL-1β, IL-6, and IL-8 production by purified monocytes from minor and major allele homozygotes following 24 hr stimulation with LPS (same samples as in D), n = 11 per group. Data are represented as mean ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001.

See also Figures S2, S3, S4 and Tables S4 and S5.
Cytokines were quantified in triplicate by ELISA. Data are represented as a mean ± SEM. *p < 0.05, **p < 0.01. 

**Figure 2. Genotype at rs12212067 Influences the Nuclear Recovery of FOXO3 during Cellular Activation**

(A) The subcellular localization of FOXO3 in monocytes during LPS stimulation (representative images). FOXO3 (red) and nucleus (DAPI, blue).

(B) The ratio of nuclear to cytoplasmic FOXO3 over time (mean immunofluorescence intensity) in LPS-stimulated monocytes from minor (G) and major (T) allele homozygotes at rs12212067 (100 ng/ml, n = 10). The dotted line indicates transition from higher signal in nucleus (above) to cytoplasm (below).

(C-D) Production of TNFα (C) and IL-10 (D) by monocytes analyzed in (B). Cytokines were quantified in triplicate by ELISA. Data are represented as mean ± SEM. *p < 0.05, **p < 0.01.

See also **Figure S5**.

**Differences in FOXO3A Transcription during Inflammation Determine when FOXO3 Reaccumulates within the Nucleus**

We next considered how differences in FOXO3A transcription might affect cytokine production. Because the downstream transcriptional program of FOXO3 is largely controlled by posttranslational modifications that determine whether it is retained within, or excluded from, the nucleus (Hedrick, 2009), we first examined how the intracellular localization of FOXO3 changed as monocytes were stimulated (Figure 2A). TNFα and IL-10 production were also measured. We showed that in unstimulated monocytes, most FOXO3 was nuclear, and TNFα production was low. Upon LPS stimulation, FOXO3 was translocated out of the nucleus (Figure 2A) and a linear increase in TNFα production was observed. This process occurred similarly in minor and major allele homozygotes, until very little nuclear FOXO3 remained after 4 hr (Figure 2B). Thereafter, a gradual increase in the amount of nuclear FOXO3 was observed (termed “nuclear recovery”), which correlated with reduced TNFα and increased IL-10 production. Strikingly, this nuclear recovery phase occurred considerably faster in minor (G) allele homozygotes than in major (T) allele homozygotes and correlated with an earlier reduction in TNFα production and an earlier increase in IL-10 production (Figures 2B–2D). This difference is consistent with the allele-specific expression differences and implies that, during inflammation, increased FOXO3A transcription in carriers of the minor (G) allele leads to faster recovery of nuclear FOXO3. This also suggests that de novo protein synthesis, rather than nuclear translocation of cytoplasmic FOXO3, is responsible for nuclear recovery; consistent with the observation that once FOXO3 is translocated into the cytoplasm, it is targeted for proteasomal degradation (Yang et al., 2008). This was confirmed by showing that if protein synthesis was inhibited, nuclear recovery of FOXO3 was substantially retarded (Figure S5).

**The Effect of rs12212067 on Monocyte Cytokine Production Is TGFβ1 Dependent**

Next we investigated how the earlier recovery of nuclear FOXO3 might alter inflammatory cytokine production. In mice, silencing Foxo3a has been shown to abrogate production of TGFβ1 (Watkins et al., 2011), an anti-inflammatory cytokine that can modulate production of other cytokines (Musso et al., 1990; Fadok et al., 1999). To determine whether TGFβ1 might contribute to the observed differences in cytokine production, we re-examined the supernatants from the earlier experiments. We found that relatively more TGFβ1 had been secreted by PBMC and monocytes from minor (G) allele homozygotes (Figure 3A) with the greatest difference, and highest concentrations, being present in the monocyte supernatants—implicating these cells as the major source of TGFβ1. To determine whether this difference might contribute to the differences in TNFα and IL-10 production, we examined the effects of blocking TGFβ1 signaling. Strikingly, we observed that the genotype-specific differences in TNFα and IL-10 production were abolished if TGFβ1 signaling was inhibited (Figure 3B)—suggesting that a TGFβ1-dependent mechanism was responsible. In support of this, differences in TGFβ1 titers from minor and major allele homozygotes were also detected in the samples from the earlier time-course experiment, with the kinetics of TGFβ1 production correlating with the differences...
in nuclear recovery of FOXO3 (Figure 3C). Moreover, the addition of exogenous TGFβ1 to stimulated monocytes of either genotype led to less TNFα and more IL-10 production—consistent with the differences observed between the genotypes—whereas blockade of TGFβ1 had the opposite effect (Figure 3D). This suggests that endogenous TGFβ1 production plays an important regulatory role in monocyte-driven inflammatory responses.

**FOXO3 Regulates TGFβ1 Production in Stimulated Monocytes**

Although these data implicate a TGFβ1-dependent mechanism in driving the genotype-specific differences in cytokine production, it was unclear how the earlier recovery of nuclear FOXO3 might mediate this. To determine whether FOXO3 directly regulated TGFβ1 production, we analyzed the TGFβ1 promoter and identified several sites at which FOXO3 was predicted to bind (Figure 4A and Table S6). To establish whether this interaction occurred during monocyte activation, we immunoprecipitated FOXO3 from stimulated monocytes and found that the DNA to which it was bound included the predicted binding site from the TGFβ1 promoter (Figure 4B), confirming that a direct protein-DNA interaction occurs. To determine the result of this interaction, we silenced FOXO3A in two monocyte cell lines, U937 (Sundström and Nilsson, 1976) and MONO-MAC6 (Ziegler-Heitbrock et al., 1988), and examined the effect on TGFβ1 transcription. In both, we showed that when FOXO3A was silenced, transcription from the TGFβ1 promoter was reduced, confirming that the FOXO3-TGFβ1 interaction promotes TGFβ1 transcription (Figure 4C). Together, these data reveal that FOXO3 induces TGFβ1 expression via a direct protein-DNA interaction in...
stimulated monocytes and explain how the earlier recovery of nuclear FOXO3 could modulate TNFα and IL-10 production in a TGFβ1-dependent manner.

TGFβ1 has also been implicated in the modulation of immune responses by apoptotic cells (Fadok et al., 1998), whereas FOXO3 is known to be proapoptotic (Brunet et al., 1999). This raised the possibility that earlier nuclear recovery of FOXO3 might also augment TGFβ1 production indirectly via apoptosis induction. To examine this, we quantified apoptosis in PBMC following LPS stimulation (using Annexin V and 7-AAD) and

---

**Figure 4. FOXO3 Regulates TGFβ1 Production in Stimulated Monocytes**

(A) Jaspar sequence logo of the FOXO3-binding site (http://jaspar.genereg.net).

(B) ChIP-qPCR analysis of the TGFβ1 promoter following FOXO3 immunoprecipitation. Enrichment for each region is shown relative to input (5 ng) and normalized against the results of a negative control immunoprecipitate (polyclonal IgG). Validated positive and negative control genomic regions were used. Controls shown are HBB (negative) and a region upstream of MSTN (positive). n = 3.

(C) Luciferase reporter assay showing effect of silencing FOXO3A on transcription from the TGFβ1 promoter in two monocyte cell lines (U937 and MONO-MAC6). No transfection (Nil) and scrambled controls (Scr) are shown. Data representative of three experiments, each with seven biological replicates.

(D) Apoptosis in monocytes from minor (G) and major (T) allele homozygotes at rs12212067 following 24 hr stimulation with LPS (100 ng/ml); assessed by flow cytometry (7-AAD +, Annexin V +), n = 12 per group.

(E) The change in the concentration of mono- and oligonucleosomes in the cytoplasm (apoptosis) and supernatant (necrosis) of monocytes following LPS stimulation (24 hr, 100 ng/ml), assessed in triplicate by ELISA. Dotted lines link paired samples; Wilcoxon signed-rank test, n = 8 per group. Data are represented as mean ± SEM, *p < 0.05, **p < 0.01, NS, nonsignificant.

See also Figure S6 and Table S6.
observed that more occurred in minor (G) allele heterozygotes (Figure 4D), consistent with the earlier recovery of nuclear FOXO3 in this genotype. To exclude a contribution from necrotic cells to this result, we quantified mono- and oligonucleosomes in the supernatant (necrosis) and cytoplasm (apoptosis) of PBMC from another cohort of minor and major allele homozygotes and again observed more apoptosis in minor allele homozygotes following stimulation (Figure 4E). We also confirmed that stimulated monocytes produced less TNFα and more IL-10 in the presence of autologous apoptotic cells and that this could be abrogated by TGFβ1-blockade (Figure S6). These data imply that FOXO3 might drive TGFβ1 production not only via a direct interaction with its promoter, but also indirectly via the control of apoptosis.

FOXO3 has also been shown to mediate some of the downstream components of TGFβ1 signaling (Wildey and Howe, 2009), raising the possibility that earlier nuclear recovery might amplify some of the effects of TGFβ1 production. However, we did not detect any genotype-specific differences in the transcription of 11 genes whose activation by TGFβ1 is FOXO dependent (Gomis et al., 2006) (data not shown), consistent with reports that this role is redundant between FOXO family members (Seoane et al., 2004).

**Froc03 Deficiency Leads to Increased Disease Severity in a Mouse Model of Colitis**

Collectively, these data provide a plausible mechanism to explain the association of the haplotype tagged by rs12212067 with prognosis in CD, particularly given the role that circulating monocytes and their intestinal derivatives play in CD pathogenesis (Geissmann et al., 2010; Khor et al., 2011; Bain et al., 2013). To provide further evidence of how altered FOXO3 function might influence intestinal inflammation, we used an in vivo model with prognosis in CD, particularly given the role that circulating monocytes and macrophages to help kill parasites (Malaguarnera and Musumeci, 2002), whereas IL-10 inhibits this protective response (Hugosson et al., 2004). We hypothesized that the effects of rs12212067: T > G would impair parasite clearance and increase the risk of severe malaria. To test this, we genotyped rs12212067 in separate cohorts of Kenyan (Williams et al., 2005) and Vietnamese patients (Tran et al., 1996) who were admitted to hospital with severe P. falciparum malaria and ethnically matched controls. In both cohorts, we found an association between the minor (G) allele and increased susceptibility to severe malaria (Tables 2 and S3), consistent with the predicted result of producing less TNFα and more IL-10 during initial infection.

**DISCUSSION**

Despite advances in complex disease genetics, remarkably little attention has been paid to whether genetics contributes to aspects of disease biology beyond simple susceptibility. Here, we identify a genetic variant in FOXO3A that associates with the prognosis, but not diagnosis, of three distinct diseases; CD, RA, and malaria. This observation has important implications for how we think about the genetics of complex disease and introduces the concept that common variants can determine the outcome of one or more diseases, without being associated with the disease itself. By focusing more attention on this aspect of disease biology, it may be possible to uncover new therapeutic targets that are relevant in several diseases and also facilitate the development of personalized medicine, both through more accurate prediction of outcome and better targeted therapies.

FOXO3 has been linked to the regulation of immune responses using systems biology (Litvak et al., 2012) and knockout mouse models (Dejean et al., 2009), although whether this was relevant
in human disease, or even occurred physiologically in humans, was unclear. By exploring the effects of the prognosis-associated variant, we have identified a pathway by which FOXO3 limits inflammatory responses in human monocytes through a paracrine TGFβ1-dependent mechanism and have confirmed the importance of this pathway in an in vivo model. This, therefore, not only provides a molecular explanation for the association of rs12212067: T > G with prognosis in each disease, but also sheds light on the role of FOXO3 in regulating monocyte-driven inflammation.

Figure 5. Loss of Foxo3a Activity Predisposes to More Severe Colitis in a Mouse Model
(A–F) Colitis was induced in littermate Foxo3a−/−, Foxo3a+/−, and Foxo3a+/+ mice using 2% DSS (7 d). Results representative of two experiments each with 5 mice per group, Mann Whitney test unless indicated. Data are represented as mean ± SEM, *p < 0.05, **p < 0.01.
(A) Light microscopy of H&E stained colonic sections from Foxo3a−/− and Foxo3a+/+ mice. Colons removed on day 12.
(B) Histological assessment of colitis severity, scored with a standard tool (Dieleman et al., 1998).
(C) Percentage change in total body weight (measured daily). Two-way ANOVA.
(D) Colon weight (day 12).
(E) Colon length (day 12).
(F) Quantitative PCR of TNFα and IL-10 mRNA extracted from paraffin-embedded colonic sections. Normalization to beta-actin (left) and CD11b (right). See also Figure S7.
Table 2. The Minor, G, Allele at rs12212067 Is Associated with Indolent RA but Increased Risk of Severe Malaria

| Phenotype                  | Meta-Analysis (RA) | Year 0 | MAF | OR | p MAF | OR | p MAF | OR | p MAF | OR | p MAF | OR | p MAF | OR | p MAF | OR | p MAF | OR | p MAF | OR | p MAF | OR | p MAF | OR | p MAF | OR | p MAF |
|----------------------------|--------------------|--------|-----|----|-------|----|-------|----|-------|----|-------|----|-------|----|-------|----|-------|----|-------|----|-------|----|-------|----|-------|----|-------|
| Severe disease             | 0.09               | 0.10   | 0.09| P  | 0.004 | 0.25| 0.017 | 1.13| 0.017 | 1.13| 0.020 | 1.13| 0.017 | 1.13| 0.017 | 1.13| 0.017 | 1.13| 0.017 | 1.13| 0.017 | 1.13| 0.017 | 1.13| 0.017 | 1.13| 0.017 |
| Mild disease (RA)          | 0.09               | 0.14   | 0.09| P  | 0.004 | 0.25| 0.017 | 1.13| 0.017 | 1.13| 0.020 | 1.13| 0.017 | 1.13| 0.017 | 1.13| 0.017 | 1.13| 0.017 | 1.13| 0.017 | 1.13| 0.017 | 1.13| 0.017 | 1.13| 0.017 |
| Indolent RA, complete absence of radiological damage in hands and feet (Larsen score = 0) | 0.09               | 0.14   | 0.09| P  | 0.004 | 0.25| 0.017 | 1.13| 0.017 | 1.13| 0.020 | 1.13| 0.017 | 1.13| 0.017 | 1.13| 0.017 | 1.13| 0.017 | 1.13| 0.017 | 1.13| 0.017 | 1.13| 0.017 | 1.13| 0.017 |
| Severe malaria, P. falciparum parasitemia complicated by features of severe malaria, requiring hospital admission. Malaria controls, ethnically matched from same region | 0.09               | 0.14   | 0.09| P  | 0.004 | 0.25| 0.017 | 1.13| 0.017 | 1.13| 0.020 | 1.13| 0.017 | 1.13| 0.017 | 1.13| 0.017 | 1.13| 0.017 | 1.13| 0.017 | 1.13| 0.017 | 1.13| 0.017 | 1.13| 0.017 |
| Indolent malaria, P. falciparum parasitemia complicated by features of severe malaria, requiring hospital admission. Malaria controls, ethnically matched from same region | 0.09               | 0.14   | 0.09| P  | 0.004 | 0.25| 0.017 | 1.13| 0.017 | 1.13| 0.020 | 1.13| 0.017 | 1.13| 0.017 | 1.13| 0.017 | 1.13| 0.017 | 1.13| 0.017 | 1.13| 0.017 | 1.13| 0.017 | 1.13| 0.017 |
| Controls (malaria)         | 0.09               | 0.14   | 0.09| P  | 0.004 | 0.25| 0.017 | 1.13| 0.017 | 1.13| 0.020 | 1.13| 0.017 | 1.13| 0.017 | 1.13| 0.017 | 1.13| 0.017 | 1.13| 0.017 | 1.13| 0.017 | 1.13| 0.017 | 1.13| 0.017 |

Phenotypes are defined as follows:
- **Severe disease**: RA patients with Larsen score > 0.
- **Mild disease (RA)**: RA patients with Larsen score = 0.
- **Indolent RA**: RA patients with Larsen score = 0, severe malaria, and P. falciparum parasitemia complicated by features of severe malaria, requiring hospital admission.
- **Severe malaria**: P. falciparum parasitemia complicated by features of severe malaria, requiring hospital admission.
- **Malaria controls**: Controls matched ethnically from the same region.

Meta-analysis was performed using Cochran-Armitage tests to determine statistical significance. Data were analyzed in PLINK (http://pngu.mgh.harvard.edu/~purcell/plink) using Cochran-Armitage tests to determine statistical significance.
statistical significance. Genotype frequencies were in Hardy Weinberg equilibrium (p > 0.05). The contribution of population structure to the association results was assessed using structure (Pritchard et al., 2000a), the Genomic Control method and a Breslow-Day test. Replication was sought in three independent replication cohorts. See also Extended Experimental Procedures.

Genotyping
Non-GWAS genotyping was performed using TaqMan predesigned SNP genotyping assays (Applied Biosciences), a custom genotyping chip (illumina Immunochip), or Sequenom MassArray technology, as indicated.

Cambridge BioResource
In vitro experiments were performed using blood samples from healthy volunteers, selected by genotype from a human bioresource (Cambridge BioResource, http://www.cambridgebioresource.org.uk). All provided informed consent. Samples were paired and age and sex matched. Investigators were blinded to sample genotype until study completion. Ethical approval was obtained from Cambridgeshire Regional Ethics Committee.

Allele-Specific Expression
A clone-based allele-specific expression assay (Rainbow et al., 2008) was performed using monocytes from six individuals heterozygous at rs12212067. Genomic DNA and pre-mRNA were extracted and amplified, and allelic ratios formed using monocytes from six individuals heterozygous at rs12212067. A clone-based allele-specific expression assay (Rainbow et al., 2008) was performed using monocytes from six individuals heterozygous at rs12212067. Genomic DNA and pre-mRNA were extracted and amplified, and allelic ratios assessed by colony genotyping (TaqMan, 96 colonies per individual per condition).

Cell Stimulations
Aliquots of 1 x 10^6 cells/ml were stimulated in Complete RPMI at 37°C, 5% CO2. 50 μl of each stimulus or control was used to produce the final concentrations. Cytokines were quantified in triplicate using cytometric bead arrays (BD), ELISAs (Quankitine, R&D Systems) or Mesoscale Discovery immunoassays (see Extended Experimental Procedures).

Immunofluorescence
Stimulated monocytes were fixed (4% PFA), blocked (2% gelatin), and stained with anti-FOXO3 (Cell Signaling) conjugated to an AF594 secondary antibody. Nuclear staining was performed using Hoechst dye. Images were captured on a Zeiss LSM510 META Confocal Microscope and analyzed with Velocity software (Perkin Elmer).

ChiP-qPCR
Chromatin from stimulated monocytes was sheared by water-bath sonication (Bioruptor, Diagenode) and FOX3 was immunoprecipitated with a ChiP-grade anti-FOX3 antibody (Abcam). Polyclonal IgG was used as a negative control. Quantitative (q)PCR was performed for a region of the TGFβ1 promoter predicted to contain a FOXO3-binding site, along with six positive and five negative controls (all previously validated in Eijkenboom et al., 2013). Input DNA was standardized (5 ng) and the data normalized to the results obtained using a polyclonal IgG immunoprecipitation.

Luciferase Reporter Assays
A firefly hLuc vector containing the TGFβ1 promoter (Promega), a pCMV renilla control and two anti-FOX3 siRNAs, or a scrambled control (Origene) were transfected into U937 (Sundström and Nilsson, 1976) and MONO-MAC6 cells (Ziegler-Heitbrock et al., 1988). Results were analyzed at 48 hr using the Dual-Glo kit (Promega) and a Glomax reader (Promega).

Mice and DSS Colitis
CS7BL/6 Foxo3aMommeR1/MommeR1 (Foxo3a−/−) mice were obtained from Emma Whitelaw (QIMR) and bred at the Australian National University (ANU). Colitis was induced in 6-week-old Foxo3a−/−, Foxo3a+/−, and Foxo3a+/+ mice (littermates) using DSS (2% in drinking water, 7 days). Body weight was assessed daily, and colon length and weight on day 12. Blinded histological assessment was made using a standard scoring system (Dielman et al., 1998), and cytokine expression quantified by qPCR from sections of paraffin-embedded colons. Approval was obtained from the ANU Animal Ethics Experimentation Committee.

Statistical Significance
Comparison of continuous variables between two groups was performed using Mann-Whitney or Wilcoxon signed-rank tests where indicated. Two-tailed tests were used as standard unless a specific hypothesis was tested. The alpha value was 0.05, unless corrected for multiple-testing.

SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven figures, and five tables, and a complete list of contributors from the UK IBD Genetics Consortium and can be found with this article online at http://dx.doi.org/10.1016/j.cell.2013.08.034.

ACKNOWLEDGMENTS
We gratefully thank the following: Cambridge BioResource (CBR) volunteers, the CBR staff for coordinating volunteer recruitment, and the CBR SAB for support; Emma Whitelaw (QIMR) for providing Foxo3aMommeR1/MommeR1 mice; Prof Adam Young (PI-NOAR) and Prof Deborah Symons (PI-ERAS) for collaboration; Alex W. Macharia, Sophie Uyyoga, Carolyne Ndilia, Emily Nyytichi, Metrine Trendeva, Johnstone Mkale, Adan Mohamed, Prophet Ingosi, and Mary Njoroge for DNA extraction at the KEMRI-Wellcome Trust Programme; and Gideon Nyutu, Kenneth Maigua, and Ruth Mwarabu for database support. This work is published with permission from the director of KEMRI, supported by NIH Biomedical Research centers in Cambridge and Manchester, and funded by the Wellcome Trust (grant program 083650/Z/07/Z, grants to J.C.L. 087007/Z/08/Z, C.A.A. 098051 and T.N.W. 091758/2/10/2). Arthritis Research UK and the Swiss Foundation for Medical Science (grant to S.V. PASMP3_134380). The Cambridge Institute for Medical Research is in receipt of Wellcome Trust Strategic Award (079895).

Received: April 12, 2013
Revised: July 8, 2013
Accepted: August 19, 2013
Published: September 12, 2013

REFERENCES
1000 Genomes Project Consortium, Abecasis, G.R., Altshuler, D., Auton, A., Brooks, L.D., Durbin, R.M., Gibbs, R.A., Hurles, M.E., and McVejan, G.A. (2010). A map of human genome variation from population-scale sequencing. Nature 467, 1061–1073.

Acilli, D., and Arden, K.C. (2004). FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell 117, 421–426.

Auffray, C., Sieweke, M.H., and Geissmann, F. (2009). Blood monocytes: development, heterogeneity, and relationship with dendritic cells. Annu. Rev. Immunol. 27, 689–692.

Bain, C.C., Scott, C.L., Uronen-Hansson, H., Gudjonsson, S., Jansson, O., Grip, O., Guilliams, M., Malissen, B., Agace, W.W., and Mowat, A.M. (2013). Resident and pro-inflammatory macrophages in the colon represent alternative context-dependent fates of the same Ly6Chi monocyte precursors. Mucosal Immunol. 6, 498–510.

Brunet, A., Bonni, A., Zigmund, M.J., Lin, M.Z., Joo, P., Hu, L.S., Anderson, M.J., Arden, K.C., Blenis, J., and Greenberg, M.E. (1999). Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96, 857–868.

Burginger, B.M., and Kops, G.J. (2002). Cell cycle and death control: long live Forkheads. Trends Biochem. Sci. 27, 352–360.

Davignon, J.L., Hayder, M., Baron, M., Boyer, J.F., Constantin, A., Apparailly, F., Poupot, R., and Cantagrel, A. (2013). Targeting monocytes/macrophages in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 52, 590–598.

Dejean, A.S., Beisner, D.R., Ch’en, I.L., Kerdiles, Y.M., Babour, A., Arden, K.C., Castrillon, D.H., DePinho, R.A., and Hedrick, S.M. (2009). Transcription factor FoxO3 controls the magnitude of T cell immune responses by modulating the function of dendritic cells. Nat. Immunol. 10, 504–513.
Crohn’s disease. Gut disease susceptibility loci. Nat. Genet. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn’s disease susceptibility loci. Nat. Genet. 42, 1118–1125.

Franke, A., McGovern, D.P., Barrett, J.C., Wang, K., Radford-Smith, G.L., Ahmad, T., Lees, C.W., Balschun, T., Lee, J., Roberts, R., et al. (2010). Genome-wide meta-analysis increases to 71 the number of confirmed Crohn’s disease susceptibility loci. Nat. Genet. 42, 1118–1125.

Geissmann, F., Manz, M.G., Jung, S., Sieweke, M.H., Merad, M., and Ley, K. (2010). Development of monocytes, macrophages, and dendritic cells. Science 327, 656–661.

Gomis, R.R., Alarcón, C., He, W., Wang, Q., Seoane, J., Lash, A., and Masagüé, J. (2006). A FoxO-Smad synexpression group in human keratinocytes. Proc. Natl. Acad. Sci. USA 103, 12747–12752.

Harada, Y., Harada, Y., Elly, C., Ying, G., Paik, J.H., DePinho, R.A., and Liu, Y.C. (2010). Transcription factors Foxo3a and Foxo1 couple the E3 ligase Cbl-b to the induction of Foxp3 expression in induced regulatory T cells. J. Exp. Med. 207, 1381–1391.

Herdick, S.M. (2009). The cunning little vixen: Foxo and the cycle of life and death. Nat. Immunol. 10, 1057–1063.

Helilö, T., Haime, L., Lappalainen, M., Fodstad, H., Paavola-Sakki, P., Turunen, U., Färkkilä, M., Krusius, T., and Kontula, K. (2003). CARD5/NOD2 gene variants are associated with familial occurring and complicated forms of Crohn’s disease. Gut 52, 558–562.

Hindorf, L.A., MacArthur, J., Morales, J., Junkins, H.A., Hall, P.N., Klemm, A.K., and Manolio, T.A. (2013). A Catalog of Published Genome-Wide Association Studies. www.genome.gov/gwastudies.

Hugoson, E., Montgomery, S.M., Premji, Z., Troye-Blomberg, M., and Björkman, A. (2004). Higher IL-10 levels are associated with less effective clearance of Plasmodium falciparum parasites. Parasite Immunol. 26, 111–117.

James, D., Young, A., Kulinskaya, E., Knight, E., Thompson, W., Ollier, W., and Dixey, J.; Early Rheumatoid Arthritis Study Group (ERAS), UK. (2004). Ortho- paedical intervention in early rheumatoid arthritis. Occurrence and predictive factors in an inception cohort of 1064 patients followed for 5 years. Rheumatology (Oxford) 43, 369–376.

Jostins, L., Ripke, S., Weersma, R.K., Duerr, R.H., McGoVERN, D.P., Hui, K.Y., Lee, J.C., Schumm, L.P., Sharma, Y., Anderson, C.A., et al.; International IBD Genetics Consortium (IIBDGC). (2012). Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 497, 119–124.

Kanehisa, M., and Goto, S. (2000). KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27–30.

Kenyon, C.J. (2010). The genetics of ageing. Nature 464, 504–512.

Kerdiles, Y.M., Stone, E.L., Beisner, D.R., McGarrill, M.A., Ch’en, I.L., Stockmann, C., Katayama, C.D., and Hedrick, S.M. (2010). Foxo transcription factors control regulatory T cell development and function. Immunity 33, 890–904.

Khor, B., Gardet, A., and Xavier, R.J. (2011). Genetics and pathogenesis of inflammatory bowel disease. Nature 474, 307–317.

Krygier, D.S., Ko, H.H., and Bressler, B. (2009). How to manage difficult Crohn’s disease: optimum delivery of anti-TNFs. Expert Rev. Gastroenterol. Hepatol. 3, 407–415.

Lee, J.C., Lyons, P.A., McKinney, E.F., Sowerby, J.M., Carr, E.J., Bredin, F., Rickenman, H.M., Ratnamwala, H., Hatton, A., Rayner, T.F., et al. (2011). Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn’s disease and ulcerative colitis. J. Clin. Invest. 121, 4170–4179.

Licastro, F., Candore, G., Lio, D., Porcellini, E., Colonna-Romano, G., France-schi, C., and Caruso, C. (2005). Innate immunity and inflammation in ageing: a key for understanding age-related diseases. Immun. Ageing 2, 8.

Litvak, V., Rathusny, A.V., Lampano, A.E., Schmitz, F., Huang, A.C., Raman, A., Rust, A.G., Bergh theler, A., Aitchison, J.D., and Aderem, A. (2012). A FoxO3-IRF7 gene regulatory circuit limits inflammatory sequelae of antiviral responses. Nature 490, 421–425.

Lundberg, A.M., Drexier, S.K., Monaco, C., Williams, L.M., Sacre, S.M., Feldmann, M., and Foxwell, B.M. (2007). Key differences in TLR3/poly I:C signaling and cytokine induction by human primary cells: a phenomenon absent from murine cell systems. Blood 110, 3245–3252.

Malagu nera, L., and Musumee, S. (2002). The immune response to Plasmodium falciparum malaria. Lancet Infect. Dis. 2, 472–478.

McClellan, J., and King, M.C. (2010). Genetic heterogeneity in human disease. Cell 141, 210–217.

McKinney, E.F., Lyons, P.A., Carr, E.J., Hollis, J.L., Jayne, D.R., Willcocks, S.G., and Van Rees, E.P. (1998). Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin. Exp. Immunol. 114, 261–267.

McKinney, E.F., Lyons, P.A., Carr, E.J., Hollis, J.L., Jayne, D.R., Willcocks, S.G., and Van Rees, E.P. (1998). Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin. Exp. Immunol. 114, 261–267.

Ménard, C., Katayama, C.D., and Hedrick, S.M. (2010). FoxO transcription factors cooperate to suppress Smad signaling. Mol. Cell 38, 155–166.

Müller, D., Seed, B., and Blumenthal, T. (2001). Phosphorylation and the regulation of IKB kinase. Annu. Rev. Immunol. 19, 603–636.

Nyberg, D.B., Espósito, L., Howlett, S.K., Hunter, K.M., Todd, J.A., Peterson, L.B., and Wicker, L.S. (2008). Commonality in the genetic control of Type 1 diabetes in humans and NOD mice: variants of genes in the IL-2 pathway are associated with autoimmune diabetes in both species. Biochem. Soc. Trans. 36, 312–315.

Rennick, D.M., Fort, M.M., and Davidson, N.J. (1997). Studies with IL-10−/− mice: an overview. J. Leukoc. Biol. 61, 389–396.

Rivollier, A., He, J., Kole, A., Valatas, V., and Kellsal, B.L. (2012). Inflammation switches the differentiation program of Ly6Chi monocytes from antiinflammatory to proinflammatory. J. Exp. Med. 210, 1399–1406.

Roche, B.A., and Lee, J.C. (2004). The genetics of aging. Aging Cell 3, 505–512.

Sundström, C., and Nilsson, K. (1976). Establishment and characterization of a murine cell system. FEBS Lett. 76, 324–327.

Symmons, D.P., and Silman, A.J. (2003). The Norfolk Arthritis Register (NOAR). Clin. Exp. Rheumatol. 21(5 Suppl 31), S94–S99.
Watkins, S.K., Zhu, Z., Riboldi, E., Shafer-Weaver, K.A., Stagliano, K.E., Sklavos, M.M., Ambs, S., Yagita, H., and Hurwitz, A.A. (2011). FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer. J. Clin. Invest. 121, 1361–1372.

Wellcome Trust Case Control Consortium. (2007). Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447, 661–678.

Wildey, G.M., and Howe, P.H. (2009). Runx1 is a co-activator with FOXO3 to mediate transforming growth factor beta (TGFbeta)-induced Bim transcription in hepatic cells. J. Biol. Chem. 284, 20227–20239.

Williams, T.N., Wambua, S., Uyoga, S., Macharia, A., Mwacharo, J.K., Newton, C.R., and Maitland, K. (2005). Both heterozygous and homozygous alpha-thalassemias protect against severe and fatal Plasmodium falciparum malaria on the coast of Kenya. Blood 106, 368–371.

Yang, J.Y., Zong, C.S., Xia, W., Yamaguchi, H., Ding, Q., Xie, X., Lang, J.Y., Lai, C.C., Chang, C.J., Huang, W.C., et al. (2008). ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat. Cell Biol. 10, 138–148.

Youngson, N.A., Vickaryous, N., van der Horst, A., Epp, T., Harten, S., Fleming, J.S., Khanna, K.K., de Kretser, D.M., and Whitelaw, E. (2011). A missense mutation in the transcription factor Foxo3a causes teratomas and oocyte abnormalities in mice. Mamm. Genome 22, 235–248.

Ziegler-Heitbrock, H.W., Thiel, E., Fütterer, A., Herzog, V., Wirtz, A., and Riethmüller, G. (1988). Establishment of a human cell line (Mono Mac 6) with characteristics of mature monocytes. Int. J. Cancer 41, 456–461.